XNASCLPT
Market cap416mUSD
Jan 15, Last price
15.12USD
1D
2.86%
1Q
25.33%
Jan 2017
344.56%
IPO
287.56%
Name
Clearpoint Neuro Inc
Chart & Performance
Profile
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 23,955 16.56% | 20,551 26.09% | |||||||
Cost of revenue | 46,401 | 36,883 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (22,446) | (16,332) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 103 | ||||||||
Tax Rate | |||||||||
NOPAT | (22,446) | (16,435) | |||||||
Net income | (22,089) 33.57% | (16,538) 7.95% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 296 | 409 | |||||||
BB yield | -0.18% | -0.20% | |||||||
Debt | |||||||||
Debt current | 848 | 561 | |||||||
Long-term debt | 17,509 | 13,518 | |||||||
Deferred revenue | 541 | 390 | |||||||
Other long-term liabilities | (9,893) | ||||||||
Net debt | (4,783) | (23,410) | |||||||
Cash flow | |||||||||
Cash from operating activities | (13,720) | (16,167) | |||||||
CAPEX | (717) | (1,146) | |||||||
Cash from investing activities | 8,949 | (10,736) | |||||||
Cash from financing activities | 296 | 409 | |||||||
FCF | (23,684) | (20,283) | |||||||
Balance | |||||||||
Cash | 23,140 | 37,489 | |||||||
Long term investments | |||||||||
Excess cash | 21,942 | 36,461 | |||||||
Stockholders' equity | (172,209) | (150,121) | |||||||
Invested Capital | 208,288 | 189,491 | |||||||
ROIC | |||||||||
ROCE | |||||||||
EV | |||||||||
Common stock shares outstanding | 24,605 | 24,182 | |||||||
Price | 6.79 -19.83% | 8.47 -24.51% | |||||||
Market cap | 167,069 -18.43% | 204,820 -11.96% | |||||||
EV | 162,286 | 181,410 | |||||||
EBITDA | (20,989) | (15,555) | |||||||
EV/EBITDA | |||||||||
Interest | 81 | ||||||||
Interest/NOPBT |